Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing Induced Chemoimmunotherapy Followed By Concurrent Chemoradiotherapy And Concurrent Chemoradiotherapy Followed By Immunotherapy In Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial

NCT07733830 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07733830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07733830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing Induced Chemoimmunotherapy Followed By Concurrent Chemoradiotherapy And Concurrent Chemoradiotherapy Followed By Immunotherapy In Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 31, 2026
Completion date
December 31, 2029
Enrollment
120 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer